A novel variant in ALG1 gene associated with congenital disorder of glycosylation: A case report and short literature review.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
08 2023
Historique:
revised: 27 04 2023
received: 23 11 2022
accepted: 04 05 2023
medline: 14 8 2023
pubmed: 19 5 2023
entrez: 19 5 2023
Statut: ppublish

Résumé

The congenital disorder of glycosylation associated with ALG1 (ALG1-CDG) is a rare autosomal recessive disease. Due to the deficiency of β1,4 mannosyltransferase caused by pathogenic variants in ALG1 gene, the assembly and processing of glycans in the protein glycosylation pathway are impaired, resulting in a broad clinical spectrum with multi-organ involvement. To raise awareness of clinicians for its manifestations and genotype, we here reported a new patient with a novel variant in ALG1 gene and reviewed the literature to study the genotype-phenotype correlation. Clinical characteristics were collected, and clinical exome sequencing was used to identify the causative variants. MutationTaster, PyMol, and FoldX were used to predict the pathogenicity, changes in 3D model molecular structure of protein, and changes of free energy caused by novel variants. The proband was a 13-month-old Chinese Han male characterized by epileptic seizures, psychomotor development delay, muscular hypotonia, liver and cardiac involvement. Clinical exome sequencing revealed the biallelic compound heterozygosity variants, a previously reported variant c.434G>A (p.G145N, paternal) and a novel variant c.314T>A (p.V105N, maternal). The literature review found that in severe phenotypes, the incidences of clinical manifestations were significantly higher than that in mild phenotypes, including congenital nephrotic syndrome, agammaglobulinemia, and severe hydrops. Homozygous c.773C>T was a strongly pathogenic variant associated with a severe phenotype. When heterozygous for c.773C>T, patients with another variant leading to substitution in amino acids within the strongly conserved regions (c.866A>T, c.1025A>C, c.1182C>G) may cause a more severe phenotype than those within less-conserved regions (c.434G>A, c.450C>G, c.765G>A, c.1287T>A). c.1129A>G, c.1076C>T, and c.1287T>A were more likely to be associated with a mild phenotype. The assessment of disease phenotypes requires a combination of genotype and clinical manifestations. The case reported herein adds to the mutations identified in ALG1-CDG and a review of this literature expands the study of the phenotypic and genotypic spectrum of this disorder.

Sections du résumé

BACKGROUND
The congenital disorder of glycosylation associated with ALG1 (ALG1-CDG) is a rare autosomal recessive disease. Due to the deficiency of β1,4 mannosyltransferase caused by pathogenic variants in ALG1 gene, the assembly and processing of glycans in the protein glycosylation pathway are impaired, resulting in a broad clinical spectrum with multi-organ involvement. To raise awareness of clinicians for its manifestations and genotype, we here reported a new patient with a novel variant in ALG1 gene and reviewed the literature to study the genotype-phenotype correlation.
METHOD
Clinical characteristics were collected, and clinical exome sequencing was used to identify the causative variants. MutationTaster, PyMol, and FoldX were used to predict the pathogenicity, changes in 3D model molecular structure of protein, and changes of free energy caused by novel variants.
RESULTS
The proband was a 13-month-old Chinese Han male characterized by epileptic seizures, psychomotor development delay, muscular hypotonia, liver and cardiac involvement. Clinical exome sequencing revealed the biallelic compound heterozygosity variants, a previously reported variant c.434G>A (p.G145N, paternal) and a novel variant c.314T>A (p.V105N, maternal). The literature review found that in severe phenotypes, the incidences of clinical manifestations were significantly higher than that in mild phenotypes, including congenital nephrotic syndrome, agammaglobulinemia, and severe hydrops. Homozygous c.773C>T was a strongly pathogenic variant associated with a severe phenotype. When heterozygous for c.773C>T, patients with another variant leading to substitution in amino acids within the strongly conserved regions (c.866A>T, c.1025A>C, c.1182C>G) may cause a more severe phenotype than those within less-conserved regions (c.434G>A, c.450C>G, c.765G>A, c.1287T>A). c.1129A>G, c.1076C>T, and c.1287T>A were more likely to be associated with a mild phenotype. The assessment of disease phenotypes requires a combination of genotype and clinical manifestations.
CONCLUSIONS
The case reported herein adds to the mutations identified in ALG1-CDG and a review of this literature expands the study of the phenotypic and genotypic spectrum of this disorder.

Identifiants

pubmed: 37204045
doi: 10.1002/mgg3.2197
pmc: PMC10422073
doi:

Types de publication

Case Reports Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2197

Informations de copyright

© 2023 Tianjin Children's Hospital and The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Orphanet J Rare Dis. 2021 Jan 6;16(1):17
pubmed: 33407696
Pediatr Int. 2016 Aug;58(8):785-8
pubmed: 27325525
Mol Syndromol. 2022 Feb;13(1):69-74
pubmed: 35221878
J Inherit Metab Dis. 2008 Jun;31(3):450-6
pubmed: 18500572
Am J Hum Genet. 2004 Mar;74(3):472-81
pubmed: 14973778
Eur J Pediatr. 2003 Jun;162(6):359-79
pubmed: 12756558
Am J Hum Genet. 2004 Mar;74(3):545-51
pubmed: 14973782
J Inherit Metab Dis. 1998 Aug;21(6):681-2
pubmed: 9762608
Dev Med Child Neurol. 2016 Oct;58(10):1085-91
pubmed: 27172925
Int Immunopharmacol. 2021 Feb;91:107308
pubmed: 33383448
Gene. 2014 Jan 25;534(2):345-51
pubmed: 24157261
Nephrol Dial Transplant. 2009 Aug;24(8):2591-4
pubmed: 19474279
Bioinformatics. 2011 Jun 15;27(12):1711-2
pubmed: 21505037
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Glycobiology. 2018 Oct 1;28(10):741-753
pubmed: 29939232
Front Genet. 2021 Sep 09;12:744884
pubmed: 34567092
Glycobiology. 2000 Mar;10(3):321-7
pubmed: 10704531
Hum Mutat. 2016 Jul;37(7):653-60
pubmed: 26931382
Mol Genet Genomic Med. 2023 Aug;11(8):e2197
pubmed: 37204045
Epilepsy Res. 2021 Aug;174:106669
pubmed: 34020146
Clin Genet. 2019 May;95(5):615-626
pubmed: 30653653
JIMD Rep. 2016;27:93-9
pubmed: 26453362
J Med Genet. 2010 Nov;47(11):729-35
pubmed: 20679665
Hum Mol Genet. 2004 Mar 1;13(5):535-42
pubmed: 14709599
J Pediatr Gastroenterol Nutr. 2021 Oct 1;73(4):444-454
pubmed: 34173795
Pediatrics. 2012 Oct;130(4):e1034-9
pubmed: 22966035
Glycobiology. 2004 Jun;14(6):559-70
pubmed: 15044395
J Inherit Metab Dis. 2017 Mar;40(2):195-207
pubmed: 28108845

Auteurs

Yan Xue (Y)

Tianjin Pediatric Research Institute, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.
Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Yiran Zhao (Y)

Tianjin Medical University, Tianjin, China.
Department of Pediatrics, Maternal and Child Health Hospital of Tangshan, Tangshan, China.

Bo Wu (B)

Department of Neurology, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.

Jianbo Shu (J)

Tianjin Pediatric Research Institute, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.
Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Dandan Yan (D)

Tianjin Pediatric Research Institute, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.
Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Dong Li (D)

Department of Neurology, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.

Xiaoli Yu (X)

Department of Neurology, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.

Chunquan Cai (C)

Tianjin Pediatric Research Institute, Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, China.
Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH